Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KardiganKARD +2.97%11 Cash Ratio is 8.94 as of Dec. 2025, which is 20% above its 10-year median of 7.45. GuruFocus rates KARD with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,384 Biotechnology companies, Kardigan ranks better than 77.31% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Kardigan Cash Ratio Related Terms
Kardigan Cash Ratio Historical Data
* Premium members only.
The historical data trend for Kardigan's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kardigan Cash Ratio Chart
Kardigan Annual Data
Trend
Dec24
Dec25
Cash Ratio
5.96
8.94
Kardigan Semi-Annual Data
Dec24
Dec25
Cash Ratio
5.96
8.94
KARD vs OCUL, GHRS, FTRE: Cash Ratio Comparison
For the Biotechnology subindustry, Kardigan's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kardigan Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kardigan's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Kardigan's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kardigan (KARD) has a Cash Ratio of 8.94 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Kardigan and its competitors. This is 20% above median its historical median of 7.45. Over the past decade, Kardigan's Cash Ratio has ranged from 5.96 to 8.94. According to the industry distribution chart, Kardigan ranks #314 out of 1384 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Kardigan's Cash Ratio too high?
Kardigan's current Cash Ratio of 8.94 is 20% above median its 10-year median of 7.45. Over the past 10 years, this metric has ranged from a low of 5.96 to a high of 8.94. The Biotechnology industry median Cash Ratio is 2.93. Kardigan's value of 8.94 is 205.1% above this industry median. Based on the distribution chart, Kardigan ranks #314 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kardigan has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kardigan's Cash Ratio compare to OCUL and GHRS?
According to the Biotechnology industry distribution chart, Kardigan ranks #314 out of 1384 companies for Cash Ratio. This places Kardigan in the top 23% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Kardigan's value of 8.94 is 205.1% above this benchmark. Historically, Kardigan's own Cash Ratio has ranged from 5.96 to 8.94 over the past decade. While the company's 10-year median is 7.45 vs. the industry median of 2.93, Kardigan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kardigan's current Cash Ratio of 8.94 is 205.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Kardigan and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kardigan's current Cash Ratio is 8.94, which is 20% above median its own 10-year median of 7.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kardigan stock overvalued right now?
Kardigan (KARD) has a current Cash Ratio of 8.94. The current Cash Ratio is 8.94, which is 20% above median its 10-year median of 7.45 and 205.1% above the Biotechnology industry median of 2.93. Kardigan's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Kardigan (KARD), the current Cash Ratio is 8.94 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score
Get the complete analysis for KARD
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KARD has been successfully added to your 
